{"symbol": "MNOV", "name": "MediciNova", "next_earnings_utc": 1595548200, "next_earnings_period_start_date_utc": 1585612800, "next_earnings_period_end_date_utc": 1593475200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q2", "next_earnings_year": 2020, "next_earnings_quarter": 2, "next_earnings_revenue_num_analysts": null, "next_earnings_revenue_consensus": 0.0, "next_earnings_eps_num_analysts": null, "next_earnings_eps_consensus": -0.115, "eps_up_revisions": 0, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 0, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 0, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "medicinova.com", "year_founded": 2000, "street_address": "4275 Executive Square", "city": "La Jolla", "state": "CA", "zipcode": "92037", "country": "United States", "phone_number": "858 373 1500", "short_description": "MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.", "long_description": "MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 235322367, "total_enterprise": 174119715, "number_of_employees": 8, "outstanding_shares": 44067859, "eps": -0.251739, "diluted_eps": -0.251739, "earnings_from_cont_operations": -10958027, "gross_profit": null, "cash": 61330267, "total_debt": 127615, "total_revenue": null, "cash_from_operations": -8974319, "net_income": -10958027, "ebitda": -11953347, "year_low_stock_price": 2.79, "year_high_stock_price": 11.57, "seekingalpha_follower_count": 2720, "image_url": "https://raw.githubusercontent.com/earnbros/earnbros.github.io/master/api/images/companies/MNOV.png"}